Esperion Therapeutics, Inc.
ESPRHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned May 30, 2026
Scan Results
Daily timeframe1 of 4 indicators bearish as of May 11
Headquartered within the healthcare sector, Esperion Therapeutics, Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United. The $805.8M market capitalization puts ESPR squarely in small-cap range for its industry. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C.
Market Cap
$805.8M
Beta
—
P/E (TTM)
—
P/E (Fwd)
12.91
EPS (TTM)
$-0.11
EPS (Fwd)
$0.24
ROE
—
ROA
12.0%
Cash
$156.2M
Total Debt
$543.8M
Free CF
-$49.2M
52W Change
301.3%
Annual Financials
Cash vs Debt
The company holds $156.2M in cash, though total debt stands at $543.8M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$49.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on assets of 12.0% further supports the picture of efficient asset utilization. Revenue has grown from $78.4M (2021) to $403.1M (2025), reflecting a 414% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ESPR.